Cargando…
B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. The current treatment paradigm involves the use of chemoimmunotherapy, when patients develop an indication for therapy. With this strategy, a majority of patients will obtain a remission, though cure remains elusive. While treatab...
Autores principales: | Arnason, Jon E, Brown, Jennifer R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918232/ https://www.ncbi.nlm.nih.gov/pubmed/27471698 http://dx.doi.org/10.2147/ITT.S37419 |
Ejemplares similares
-
Population Pharmacokinetics and Exposure Response Assessment of CC‐292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia
por: Li, Yan, et al.
Publicado: (2017) -
Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
por: Ribrag, Vincent, et al.
Publicado: (2022) -
“Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia''
por: Oppezzo, P, et al.
Publicado: (2013) -
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study
por: Schafer, Peter H., et al.
Publicado: (2019) -
Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton’s Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease
por: Ziouti, Fani, et al.
Publicado: (2021)